

Experimental Study of the Effect of Low Dose Aspirin and Betamethasone on the Patency Rate of Microvascular Polytetrafluoroethylene Grafts (PTFE)

Thesis Submitted for Partial Fulfillment of
The M.D. Degree in
Plastic and Reconstructive Surgery

Presented by

Hossam El din Mohammed Abuelatta
M.B.B.Ch, M.Sc. in General Surgery

Supervised by

Prof. Dr. Ikram Ibrahiem Safe

*Professor and Head of Plastic and Reconstructive Surgery Department
Faculty of Medicine, Ain Shams University*

Prof. Dr. Ayman Abu Elmakarem Shaker

*Professor of Plastic and Reconstructive Surgery
Faculty of Medicine, Ain Shams University*

Dr. Ashraf Maher Farid

*Assistant Professor of Plastic and Reconstructive Surgery
Faculty of Medicine, Ain Shams University*

Dr. Hale Tufan

*Assistant Professor of Pharmacology
Faculty of Medicine, Baskent University
Ankara, Turkey*

Faculty of Medicine
Ain Shams University
2005

*Thank you very much my **Great God**, I
relate to you any success in my life.*

Acknowledgement

First of all, I would like to express my deep gratitude and respect to **Prof. Dr. Ikram Safe** Head of Plastic and Reconstructive Surgery Department for giving me the honor to be under his supervision and for his continuous valuable advice, support and time that he gave to me during this work.

I am truly indebted to Prof. Dr. **Ayman Abu Elmakarem** for his kind supervision, wise help and his follow up throughout the study.

My sincere thanks and appreciation go to **Prof. Dr. Ashraf Maher** for his meticulous supervision and for providing me a lot of encouragement and support during this study.

I would like to express my sincere thanks and appreciation to **Prof. Dr. Mostafa Hameda** for giving me the opportunity to do this work in Baskent University and for his continuous encouragement.

Finally my respect and thanks to **all the members** of Plastic Surgery Department of Ain Shams University.

Special Acknowledgement

All my gratitude and respect go to Prof. Dr. Mehmet Haberal President of Baskent University in which I did this study. I would like to express my thanks to him for giving me this valuable chance of doing this study in his university.

No words might give Prof. Dr. Hale Tufan her rights of thanks for her endless help, support and supervision during this work, I am truly indebted to her.

I wish to express my thanks to Prof. Dr. Nihan Haberal Professor of Pathology and Prof. Dr. Attila Sengen Professor of Vascular Surgery and all the technicians in the research center of Baskent University for their kind help throughout all this study.

List of contents

	<i>Page</i>
☞ <i>Introduction</i>	<i>1</i>
☞ <i>Aim of the Work</i>	<i>6</i>
☞ <i>Review of Literature</i>	<i>7</i>
☞ <i>Arterial Grafts</i>	<i>7</i>
☞ <i>Vein Grafts</i>	<i>12</i>
☞ <i>Vascular Synthetic Grafts</i>	<i>29</i>
☞ <i>Improving Vascular Synthetic Grafts Patency</i>	<i>52</i>
☞ <i>Materials and Methods</i>	<i>81</i>
☞ <i>Results</i>	<i>102</i>
☞ <i>Discussion</i>	<i>135</i>
☞ <i>Summary and Conclusion</i>	<i>145</i>
☞ <i>References</i>	<i>149</i>
☞ <i>Arabic Summary</i>	<i>174</i>

List of Abbreviations

<i>Abbreviation</i>	<i>Word</i>
PTFE	Polytetrafluoroethylene
PUs	Polyurethanes
IH	Intimal hyperplasia
VSMC	Vascular smooth muscle cell
MMPs	Metalloproteinase
PDGF	Platelet derived growth factor
EDRF	Endothelial derived relaxing factor
NO	Nitrous Oxide
ET	Endothelin
ECE	Endothelin-converting enzyme
ECs	Endothelial cells
LDF	Laser doppler flometry
BPU	Blood perfusion unit
PE	phenylephrine
ITB	Isolated tissue bath
L-NAME	Nitro-L-arginine methyl ester

List of Figures

<i>Figure No.</i>	<i>Description</i>	<i>Page</i>
Figure 1	Differential dilatation of vein graft.	23
Figure 2	Suturing vein graft at angle.	23
Figure 3	Microstructure of PTFE.	31
Figure 4	Patency rate & graft survival time.	39
Figure 5	Normal vessel structure.	42
Figure 6	Quiescent state of VSMCs.	46
Figure 7	The activated state of VSMCs.	47
Figure 8	Response of vessel to injury.	49
Figure 9	Response of vessel to inflammation.	50
Figure 10	Endothelin-1 (ET-1) biosynthesis.	61
Figure 11	Decellularized vein.	78
Figure 12-18	Preparation and dissection.	85-86
Figure 19-20	LDF system and reading.	88
Figure 21-24	Anastomosis and patent graft.	88-90
Figure 25	(LDF 2) reading.	90
Figure 26	Skin closure.	90
Figure 27	Ackland test.	96
Figure 28	LDF measurements.	96
Figure 29	ITB system.	99
Figure 30	ITB measurements.	99
Figure 31	Macroscopic picture of patent grafts.	104
Figure 32	Macroscopic picture of closed grafts.	105
Figure 33	Percentage of patent grafts in each group.	108
Figure 34	LDF measurements before and after grafting.	109
Figure 35	LDF before grafting and after sacrifice.	109

Figure 36	Photomicrograph showing No IH formation.	112
Figure 37	Photomicrograph showing IH formation.	112
Figure 38	Percentage of IH in all groups.	114
Figure 39	Percentage and course of IH in subgroups of control group.	117
Figure 40	Percentage and course of IH in subgroups of aspirin group.	117
Figure 41	Percentage and course of IH in subgroups of betamethasone.	120
Figure 42	Percentage and course of IH in subgroups of BQ123 group.	120
Figure 43	Percentage and course of IH in subgroups of phosphoramidon group.	124
Figure 44	Percentage of IH at the proximal and distal anastomosis sites.	124
Figure 45	Relation between IH and patency rate.	125
Figure 46	Photomicrograph showing endothelialization of the graft near anastomosis site in 2 weeks.	126
Figure 47	Photomicrograph showing complete endothelialization of mid graft area in 6 weeks.	126
Figure 48	Photomicrograph showing mild inflammatory reaction & fibrin deposition in 4 weeks.	128
Figure 49	Photomicrograph showing sever inflammatory reaction in 4 weeks control subgroup.	128
Figure 50	Photomicrograph showing calcification in the graft wall in control group.	129
Figure 51	Photomicrograph showing calcification in IH layer in control group.	129

Figure 52	Photomicrograph showing deficient endothelialization in mid graft area in 6 weeks betamethasone subgroup.	130
Figure 53	Photomicrograph showing patent aneurysm with organized thrombus inside the lumen.	130
Figure 54	Graft thrombosis in 4 weeks subgroup.	133
Figure 55	Photomicrograph showing thrombus in the graft.	133
Figure 56	Patent aneurysm.	134
Figure 57	Photomicrograph showing graft surrounded by a sac filled with pus.	134

List of Tables

<i>Table No.</i>	<i>Description</i>	<i>Page</i>
Table 1	Effects of ET on various tissues.	64
Table 2	Patency rate in groups.	107
Table 3	ITB results.	111
Table 4	Percentage of IH in groups.	113
Table 5	Data of control group.	115
Table 6	Data of aspirin group.	116
Table 7	Data of betamethasone group.	118
Table 8	Data of BQ123 group.	119
Table 9	Data of phosphoramidon group.	121
Table 10	Percentage of IH at the proximal anastomosis sites in all groups.	122
Table 11	Percentage of IH at the distal anastomosis sites in all groups.	123

List of Erratum

Page number	False word	Correction
I	Flometry	Flowmetry
7	1948	1978
7	Makes	Make
19	Radiated	Irradiated
27	The	That
40	Heparin	Heparan
52	No endothelin inhibitors	
128	Depostion	Deposition
128	Sever	Severe

References:

Lime CH., Mardini S., Lim YT., Yeh IT., Wei FC, Chen HC. (2004): Sixty-Five clinical cases of free tissue transfer using long AV fistulas or vein grafts. J. trauma: 56 (5), 1107.

The advances of microvascular surgery over the years have resulted in an increased need for small diameter vessel replacements. Reversed autologous vein grafts are presently the most suitable material for use as arterial substitutes in microsurgical procedures. However dissecting, harvesting and preparing a vein graft add time to any microsurgical procedure, also the choice of veins may be limited by a number of factors like trauma or obliterative vascular disease. Additionally one or more veins must be sacrificed, a donor site scar is left and usually one must compromise in terms of matching sizes and diameters between vein graft and recipient vessel (*Lanzetta, 1998*).

Bridging microvascular defects with synthetic grafts would have the great advantage of providing a choice of the most optimal size and shape with decreased operative time. Large-diameter synthetic grafts with their various lengths and numerous configurations have gradually found their place in vascular surgery and are currently very widely used in a great variety of clinical situations. However small diameter synthetic grafts have not left the laboratory as they are disappointing in their high rate of thrombosis and still considered unreliable (*Lanzetta, 1998*).

Nowadays, there are many types of synthetic grafts on the horizon, such as PTFE, Dacron and Polyurethanes (PUs) grafts.

The ideal vascular graft should be characterized by its mechanical attributes and post-implantation healing responses. Mechanical strength is a paramount issue; grafts placed in the arterial circulation should be capable of withstanding long-term haemodynamic stress without material failure which might be catastrophic. Availability, suturability and simplicity of handling are desirable for minimizing operating time and risk. The graft should be resistant to both thrombosis and infection and optimally would be completely incorporated by the body to yield a new vessel resembling a native artery in structure and function (*Conte, 1998*).

The most widely used synthetic graft is PTFE because of a relatively low inherent thrombogenicity and satisfactory tissue healing. PTFE also exhibits physical properties such as biocompatibility, inertness, negative charge and hydrophobia which all help to reduce the occurrence of thrombosis with promising patency rate (*Cooley, 1998*).

However with such ideal characteristic, authors have reported highly varying patency rate ranging from complete failure to as high as 90 % patency rate after 2 weeks by *Parsa and Spira (1979)*, *Caudrs (1984)*, *Daniel (1985)*, *Zdanowski et*

al. (1992), Van der lei and Robinson (1993), Lemson et al. (2000).

The factors responsible for synthetic grafts failure were thoroughly investigated and optimized, as regard the graft materials by using PTFE grafts (with radial support, large pores and fibril length of at least 60 μm) and as regard the technical error (by meticulous techniques and the intra-operative observation of the anastomosis for 1 hour to insure early patency). Therefore the remaining factor incriminated in synthetic grafts failure is **intimal hyperplasia (IH)** that develops at the anastomosis sites with subsequent slowing of the circulation, platelet aggregation and thrombus formation (*Demiri et al., 1999*).

Intimal hyperplasia is a process by which the cell population increases within the innermost layer of the vessel wall, such as occurs physiologically during closure of the ductus arteriosus and during involution of the uterus. It also occurs pathologically in pulmonary hypertension, atherosclerosis, transplanted organs, and after angioplasty. The underlying cause of intimal hyperplasia is migration and proliferation of vascular

smooth muscle cells (VSMCs) from media to intima (phenotypic modulation) (*Newby and Zaltsman, 2000*).

The key stimuli for IH are injury, inflammation and increased mean wall stress. They activate heparanases and a cascade of proteases that together loosen the connections of the extracellular matrix with the VSMCs surface which provides the trigger for phenotypic modulation. Also peptide growth factors agents such as thrombin, endothelin-1 and angiotensin-II and inflammatory cytokines act co-operatively to trigger proliferation and migration of VSMCs (*Newby and Zaltsman, 2000*).

Complex interactions with platelets and subsequent release of platelets derived factors and interaction with the adjacent endothelial cells lead to collagen and fibrin deposition and the development of IH. A successful drug that could limit this hyperplastic response may help to improve patency rate of synthetic grafts (*Petrik et al., 1998*).

Therefore the extent of the intimal hyperplasia formation may be theoretically decreased by the use of pharmacological drugs that might inhibit (1) the platelets activity (Antiplatelet) like *Low Dose Aspirin*, (2) the fibrin deposition

(Glucocorticoids) like *Betamethasone*, (3) The action of endothelin (Endothelin Receptor Antagonist) like *BQ123*, (4) the endothelin formation (Endothelin Converting Enzyme Inhibitor) like *Phosphoramidon*, with subsequent improvement of the patency rate.
